Autopsy report · NCT00809302

Efficacy and Safety Study of Aplindore in Patients With Early Parkinson Disease

“Neurogen acquired by Ligand Pharmaceuticals - no further support for study. No safety concerns identified.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 10 months before it stopped.
• 9 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Neurogen Corporation

Sponsor type

Industry

Conditions

Early Parkinson Disease

Interventions

aplindore MR tablets or Placebo

Participants

9

Sites

25

Countries

United States

Trials that died the same way

• Efficacy and Safety Study of Aplindore in Patients With Restless Legs Syndrome
  “Neurogen acquired by Ligand Pharmaceuticals - no further support for the study. No safety concerns identified.” (99% match in meaning)
• Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia
  “Study ATS3020 was closed due to business reasons. Neurocrine Biosciences will continue to conduct study ATS3019 (NCT05110157). There were no unexpected safety findings for this compound that motivated the decision.” (58% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.